The HER Project: HRD in EGFR-mutated NSCLC

This observational retrospective-prospective study aims to evaluate the prevalence of homologous recombination deficiency (HRD) in metastatic EGFR mutated NSCLC and to assess its correlation with clinical and molecular features. Based on the hypothesis that HRD identifies a distinct EGFRm subgroup with prognostic value and a potential sensitivity to PARP inhibitor-based strategies, translational analysis will be performed with multiple pre-clinical models, ranging from human cancer cells to murine models.

NCT Number	NCT07303218
Lead Sponsor	IRCCS San Raffaele
Conditions	EGFR, Non Small Cell Lung Cancer, Homologous Recombination Deficiency, PARP Inhibitor
Enrollment	100 participants
Start Date	2025-12-01
Primary Completion	2029-12-31 (estimated)
Study Completion	2032-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-12-31